Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF) signed a major $205 million licensing deal with Nxera for its Duchenne Muscular Dystrophy (DMD) treatment in the Asia Pacific region. This includes a $40 million upfront payment and future milestones for expansion into Japan and Korea. Watch more
Solvonis Therapeutics PLC (LSE:SVNS) secured a new US patent for its PTSD drug program. The company is aiming for lead candidate selection in early 2026 as it tackles a massive unmet medical need. Watch more
Seeing Machines Ltd (AIM:SEE, OTC:SEEMF) is set to receive a $14 million lump sum royalty from a major car maker. The company also hit a huge milestone by reaching a cash-flow breakeven run rate this past December. Watch more
Connecting Excellence Group Plc (AQSE:XCE) is launching a unique Bitcoin-denominated bond to protect holders during market swings. It now holds over 41 Bitcoin on its balance sheet with a goal to reach 1,000. Watch more
Tooru PLC (AIM:TOO) is scaling its wellness brands after securing new distribution wins with Tesco and the Co-Op. A recently extended facility from Shawbrook Bank provides additional capital to support growth, particularly for its OAF brand. Watch more
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF) expects a pivotal year with upcoming efficacy data from its dog longevity trial. Success here could trigger a licensing deal and bring in non-dilutive money for the company. Watch more
Follow us and subscribe on YouTube, our social channels and on proactiveinvestors.co.uk.
